Anchor, Spacer, and Ligand-Modified Engineered Exosomes for Trackable Targeted Therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapeutics

Background:

• Exosomes show promise as anticancer agents but lack specificity and have short half-lives, limiting clinical use.
• High therapeutic doses are often required due to poor targeting and rapid clearance.
• Existing exosome modification methods can damage the vesicles or destabilize incorporated agents.

Purpose of the Study:

• To engineer exosomes with an active targeting system for improved specificity and therapeutic efficacy.
• To develop a modular platform for exosome modification that integrates targeting, imaging, and drug delivery.
• To evaluate the efficacy of modified exosomes in targeting and treating melanoma.

Main Methods:

• Engineered exosomes with a membrane Anchor-Spacer-Ligand (ASL) system, incorporating BODIPY, PEG, and cyclic RGD peptide.
• Incorporated ASL system into exosome membranes for enhanced stability and active targeting.
• Encapsulated doxorubicin into ASL-modified exosomes (dAExs) for drug delivery.
• Evaluated targeting specificity to B16F10 melanoma cells in vitro and in vivo.
• Assessed the therapeutic efficacy of dAExs in inhibiting melanoma growth.

Main Results:

• ASL-modified exosomes (AExs) demonstrated enhanced stability and active targeting capabilities.
• AExs specifically targeted B16F10 melanoma tumor sites via cyclic RGD and integrin interaction.
• AExs provided a built-in bioimaging modality for tracking.
• Doxorubicin-loaded AExs (dAExs) significantly inhibited melanoma growth both in vitro and in vivo.
• ASL modification facilitated modular integration of tracking, targeting, and drug delivery.

Conclusions:

• ASL-modification transforms exosomes into versatile therapeutic vehicles with integrated in vivo tracking, targeting, and drug delivery.
• This modular approach overcomes key limitations of exosome-based therapies, enhancing stability and specificity.
• The ASL platform holds potential for advancing exosome-based applications beyond cancer therapy.